1st Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Period 1st Quarter 2013 Filed Apr 22, 2013 Signed by Kathryn Biberstein, SVP and General Counsel

Official filing

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
ALKERMES, INC.
Client
ALKERMES, INC.
Income
—
Expenses
$92,883
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 22, 2013 $92,883 Replaced
1st Quarter - Amendment May 3, 2013 $120,248 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Discuss need for educational resources and status of Vivitrol in public health.

LobbyistCovered position, as disclosed
ROBERT FORMAN —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.